<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03011736</url>
  </required_header>
  <id_info>
    <org_study_id>I 274915</org_study_id>
    <secondary_id>NCI-2016-01974</secondary_id>
    <secondary_id>I 274915</secondary_id>
    <nct_id>NCT03011736</nct_id>
  </id_info>
  <brief_title>Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism</brief_title>
  <official_title>Single-Arm, Non-inferiority Study of Omission of Intraoperative Intact Parathyroid Hormone (PTH) During Minimally Invasive Parathyroidectomy for Primary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies the omission of intact parathyroid hormone testing during surgery&#xD;
      in treating patients with primary hyperparathyroidism. Omission of intact parathyroid hormone&#xD;
      testing during parathyroid gland removal may help patients with primary hyperparathyroidism&#xD;
      to decrease their time under anesthesia, and decrease the overall time and cost of surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the non-inferiority of omission of parathyroid hormone (PTH) in patients who&#xD;
      meet the biochemical and radiological criteria compared to current standard of care (i.e. use&#xD;
      of intraoperative parathyroid hormone testing).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Cost-analysis to determine savings of omission of intraoperative PTH testing.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo standard minimally invasive parathyroidectomy without PTH testing during&#xD;
      surgery.&#xD;
&#xD;
      After completion of study, patients are followed up at 2 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2016</start_date>
  <completion_date type="Actual">December 24, 2018</completion_date>
  <primary_completion_date type="Actual">July 12, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure of primary hyperparathyroidism following surgery with intraoperative PTH omission</measure>
    <time_frame>At 2 weeks</time_frame>
    <description>Will be evaluated using a binomial exact test. If all N=60 patients achieve cure then the proposed surgery with intraoperative PTH testing committed will be considered non inferior. A 95% confidence interval about pi will be obtained.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative cost analysis</measure>
    <time_frame>At 2 weeks</time_frame>
    <description>cost analysis will be based on operative time and omission of intraoperative PTH levels.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Parathyroid Gland Adenoma</condition>
  <condition>Primary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Supportive Care (parathyroidectomy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo standard minimally invasive parathyroidectomy without PTH testing during surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Supportive Care (parathyroidectomy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Parathyroidectomy</intervention_name>
    <description>Undergo parathyroidectomy</description>
    <arm_group_label>Supportive Care (parathyroidectomy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive 4 dimensional computed tomography (4D CT) for single gland (adenoma) primary&#xD;
             hyperparathyroidism&#xD;
&#xD;
          -  Preoperative serum calcium levels &gt;= 10.9 mg/dL&#xD;
&#xD;
          -  Preoperative parathyroid hormone (PTH) elevated beyond normal range or inappropriately&#xD;
             high for associated calcium level&#xD;
&#xD;
          -  Patient has no history of prior neck surgery or external radiation to neck for&#xD;
             malignant conditions&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of =&lt; 2&#xD;
&#xD;
          -  Subject or legal representative must understand the investigational nature of this&#xD;
             study and sign an Independent Ethics Committee/Institutional Review Board approved&#xD;
             written informed consent form prior to receiving any study related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has recurrent hyperparathyroidism&#xD;
&#xD;
          -  4D CT positive for multiple gland disease&#xD;
&#xD;
          -  Patient has inability to tolerate 4D CT scan (for example; contrast intravenous (IV)&#xD;
             allergy, claustrophobia, renal disease)&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Pregnant or nursing female subjects; may be determined in the preoperative evaluation&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements&#xD;
&#xD;
          -  Any condition which in the investigator's opinion deems the subject an unsuitable&#xD;
             candidate to undergo observational study (may also include preoperative testing&#xD;
             results including electrocardiography [EKG], chest x-ray, or pulmonary function tests&#xD;
             that preclude a wide excision in the operating room)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshim Kukar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 4, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

